AlphaStocks

AMPH vs OGN

As of Sep 20, 2026, Amphastar Pharmaceuticals (AMPH) scores 7.5/10 and Organon (OGN) 6.2/10 on AlphaStocks' five-model composite, so AMPH scores higher.

AMPH

Amphastar Pharmaceuticals, Inc.

7.5

Strong Buy

$23.60

OGN

Organon & Co.

6.2

Consider Buy

$13.69

AMPH vs OGN: Which is the Better Investment?

Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5/10 while Organon & Co. (OGN) scores 6.2/10 on AlphaStocks' composite model. Amphastar Pharmaceuticals, Inc. has the higher composite rating of Strong Buy.

This comparison is algorithmically generated and is not financial advice.

MetricAMPHOGN
Scores & Fundamentals
Composite Score7.5/106.2/10
RatingStrong BuyConsider Buy
Price$23.60$13.69
P/E Ratio19.1
ROE15.4%
Market Cap$1B$4B
Fair Value
Dividend Yield2.5%
Sector Rank#4 of 168#42 of 168
Model Verdicts
PiotroskiAttractiveAttractive
BuffettAttractiveNeutral
GrahamAttractiveCaution
LynchAttractiveCaution
GreenblattAttractiveStrong
View full AMPHanalysis →View full OGNanalysis →

Related comparisons

Compare any two stocks →

AMPH vs OGN: Which Stock Scores Higher?

Amphastar Pharmaceuticals, Inc. (AMPH) and Organon & Co. (OGN) are both in the Health Care sector. AMPH currently leads with a composite score of 7.5/10 (Strong Buy) compared to OGN's 6.2/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer